Passage Bio is a genetic medicines company focused on developing gene therapies for central nervous system diseases, particularly rare lysosomal storage disorders and neurodegenerative conditions. The company's pipeline includes PBGM01 for infantile GM1 gangliosidosis, PBFT02 for frontotemporal dementia caused by progranulin deficiency, and PBKR03 for infantile Krabbe disease. Additional programs target metachromatic leukodystrophy, amyotrophic lateral sclerosis, and Huntington's disease.
The company maintains a research collaboration with the University of Pennsylvania's Gene Therapy Program and has entered into development services and clinical supply agreements with Catalent Maryland. These partnerships support Passage Bio's research and manufacturing capabilities for its gene therapy candidates.
Based in Philadelphia, Pennsylvania, Passage Bio operates with approximately 60 full-time employees. The company was incorporated in Delaware in 2017 and is publicly traded on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.07 | $-1.07 | +42.5% | |
| 2023 | $-1.86 | $-1.86 | +25.6% | |
| 2022 | $-2.50 | $-2.50 | +28.2% | |
| 2021 | $-3.48 | $-3.48 | — | |
| 2020 | — | — | — |